Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

The high relapse rates following initial treatments, make the search for novel immunotherapies urgent. However, the ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced results from a study demonstrating the efficacy of the Cellworks Therapy ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 -- Organizational restructuring to focus resources on ...

WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

Tumors find different ways to avoid immune cell detection and proliferate in their environment. Antitumor immune cells will ...

The cancer microenvironment, or tumour microenvironment, describes the non-cancerous cells present in the tumour. These include fibroblasts, immune cells and cells that comprise the blood vessels.